Last Updated : July 24, 2024
Details
FilesGeneric Name:
trifluridine and tipiracil
Project Status:
Complete
Therapeutic Area:
Metastatic colorectal cancer
Manufacturer:
Taiho Pharma Canada, Inc.
Call for patient/clinician input open:
Brand Name:
Lonsurf
Project Line:
Reimbursement Review
Project Number:
PC0330-000
Call for patient/clinician input closed:
Tumour Type:
Gastrointestinal
NOC Status at Filing:
N/A
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
LONSURF, in combination with bevacizumab, for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
LONSURF, in combination with bevacizumab, for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 04-Jul-23 |
|---|---|
| Call for patient/clinician input closed | 25-Aug-23 |
| Clarification: - Patient input submission received from Colorectal Cancer Canada, and Colorectal Cancer Resource & Action Network (CCRAN) | |
| Submission received | 15-Aug-23 |
| Submission accepted | - |
| Review initiated | 30-Aug-23 |
| Draft CADTH review report(s) provided to sponsor for comment | 16-Nov-23 |
| Deadline for sponsors comments | 27-Nov-23 |
| CADTH review report(s) and responses to comments provided to sponsor | 21-Dec-23 |
| Expert committee meeting (initial) | 10-Jan-24 |
| Draft recommendation issued to sponsor | 23-Jan-24 |
| Draft recommendation posted for stakeholder feedback | 01-Feb-24 |
| End of feedback period | 15-Feb-24 |
| Final recommendation issued to sponsor and drug plans | 29-Feb-24 |
| Final recommendation posted | 19-Mar-24 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | 14-Mar-24 |
| CADTH review report(s) posted | 14-Jun-24 |
Files
Last Updated : July 24, 2024